Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
15/05/2024 | 14:35 | GlobeNewswire Inc. | ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
15/05/2024 | 14:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
15/05/2024 | 14:25 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
14/05/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
29/04/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
04/04/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
25/03/2024 | 13:17 | GlobeNewswire Inc. | ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
18/03/2024 | 12:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
14/03/2024 | 12:57 | GlobeNewswire Inc. | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024 | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
08/03/2024 | 23:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
08/03/2024 | 23:00 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
29/02/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
28/02/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
22/02/2024 | 13:47 | GlobeNewswire Inc. | ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
14/02/2024 | 22:34 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
14/02/2024 | 13:53 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
07/02/2024 | 14:02 | GlobeNewswire Inc. | ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
31/01/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
24/01/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
19/01/2024 | 12:19 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
17/01/2024 | 13:52 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
10/01/2024 | 14:06 | GlobeNewswire Inc. | ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
04/01/2024 | 13:50 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
03/01/2024 | 14:07 | GlobeNewswire Inc. | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
18/12/2023 | 14:12 | GlobeNewswire Inc. | ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024” | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
14/12/2023 | 13:01 | GlobeNewswire Inc. | ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
08/12/2023 | 22:44 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
07/12/2023 | 17:20 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
07/12/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
07/12/2023 | 03:00 | GlobeNewswire Inc. | ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |